AC Immune is a brand-new company record, and its full research profile isn't ready yet.
acimmune.comCrawled Oct 25, 2026
AC Immune advances one of the industry’s broadest & most diverse clinical-stage pipelines focused on neurodegenerative diseases, Alzheimer's or Parkinson's
AC Immune's experienced team is pioneering precision medicine targeting neurodegeneration, and has an integrated approach to CNS-specific therapies
AC Immune’s platforms support multiple therapeutic and diagnostic approaches, expanding its pipeline of product candidates.
AC Immune advances clinical trials for its broad portfolio of precision medicine therapies targeting neurodegenerative diseases.
AC Immune describes its approach to diagnosing, treating, and preventing neurodegeneration through its latest scientific publications.
AC Immune develops breakthrough therapies for neurodegeneration using pioneering science and precision medicine.
AC Immune’s teams combines a proven track record in entrepreneurial management, World renowned scientists & Recognized leaders in neurodegenerative diseases
AC Immune partners its product candidates strategically to maximize shareholder value while managing risk.
AC Immune is a clinical-stage biopharmaceutical company & a global leader in precision medicine to diagnose, treat and prevent neurodegenerative diseases
Pioneering Precision Medicine | AC Immune works with suppliers offering a high standard of service & products as well as demonstrating ethics and integrity
AC Immune SA develops precision medicine for neurodegenerative diseases, including Alzheimer’s and Parkinson’s, using advanced technology platforms.
AC Immune designs vaccine strategies to prevent Alzheimer’s and Parkinson’s diseases.
Targeting misfolded self-proteins pioneering precision medicine for neurodegenerative diseases: Alzheimer's disease & Parkinson's disease | AC Immune SA